Kevin Coleman
Family Medicine · Rifle, CONPI 1710977871
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $500 and has fallen 78.2% since, to $109 in 2025.
Across 112 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$373
- AstraZeneca$292
- Johnson & Johnson$142
- Pfizer$140
- Eisai Inc.$136
- Lilly USA, LLC$104
- plus $840 from 23 others
What the payments were for
- Food & beverage$2,025100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $373 |
| AstraZeneca | 17 | $292 |
| Johnson & Johnson | 8 | $142 |
| Pfizer | 9 | $140 |
| Eisai Inc. | 7 | $136 |
| Lilly USA, LLC | 7 | $104 |
| Acadia Pharmaceuticals Inc | 1 | $81 |
| Astellas Pharma US Inc | 4 | $78 |
| Amgen | 4 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| Biohaven Pharmaceuticals, Inc. | 3 | $68 |
| Lundbeck LLC | 2 | $61 |
| GSK | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Biodelivery Sciences International, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Merck | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$2,025 in reported general payments places this provider in the 85th percentile of 2,079 family medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Digoxin | 17 | $389 |
| Gabapentin | 16 | $280 |
| Omeprazole | 21 | $272 |
| Metoprolol Succinate | 16 | $254 |
| Levothyroxine Sodium | 20 | $238 |
| Metformin Hcl | 12 | $181 |
| Simvastatin | 12 | $123 |
| Amlodipine Besylate | 13 | $81 |
| Lisinopril | 11 | $72 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Rifle
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
- Gregory MaederWestminster$95K
- Paul SimmonsGrand Junction$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.